Page 390 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
stage ≤T2 and
age ≤80 yr.
Univ. of North Patients with PSA was monitored at 3 mo, then every 6 mo. Hematocrit and NR Development of
Carolina, US 155 stage T1c creatinine were measured every 6 mo. palpable disease in
prostate cancer DER, gross hematuria,
1991-1996 who chose to be urinary tract infection,
on expectant bothersome symptoms
management. All due to bladder outlet
patients had DRE obstruction, metastatic
enzymatic PAP disease as shown in
values obtained physical examination
prior to or at least or radiographic
4 wk after examination, PSA
prostatic biopsy, level increase in 3
radionuclide bone consecutive
scan, and measurements and
the absence of a the total increase was
visible lesion upon > 5 ng/ml.
transrectal US
that was proven
malignant
histologically.

C-113